Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
Background: Deferasirox (DFX) is commonly used to reduce the chronic iron overload (IO) in pediatric patients. However, the drug is characterized by a large pharmacokinetic variability and approximately 10% of patients may discontinue the treatment due to toxicities. Therefore, the present retrospec...
Saved in:
Main Authors: | Laura Galeotti (Author), Francesco Ceccherini (Author), Carmen Fucile (Author), Valeria Marini (Author), Antonello Di Paolo (Author), Natalia Maximova (Author), Francesca Mattioli (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis
by: Fucile C, et al.
Published: (2018) -
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
by: Giacomo Luci, et al.
Published: (2021) -
Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients
by: Natalia Maximova, et al.
Published: (2022) -
Pharmacokinetic-Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
by: Carmen Flores-Pérez, et al.
Published: (2023) -
Evaluation of pharmacokinetic pharmacodynamic target attainment of meropenem in pediatric patients
by: Abdullah Alsultan, et al.
Published: (2024)